Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives $60.00 Average PT from Analysts
Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month target price among […]
10 Oct 09:36 · The Markets Daily